Vetr upgraded shares of MannKind Co. (NASDAQ:MNKD) from a hold rating to a strong-buy rating in a research note published on Wednesday, MarketBeat Ratings reports. Vetr currently has $0.90 price target on the biopharmaceutical company’s stock.

Several hedge funds and institutional investors recently bought and sold shares of MNKD. Parametrica Management bought a new position in MannKind during the fourth quarter valued at approximately $429,000. McQueen, Ball & Associates bought a new position in MannKind during the fourth quarter valued at approximately $32,000. Finally, Simplex Trading increased its position in MannKind by 249.7% in the fourth quarter. Simplex Trading now owns 2,661 shares of the biopharmaceutical company’s stock valued at $881,000 after buying an additional 1,900 shares during the period.

MNKD has been the topic of a number of other reports. Goldman Sachs reissued a sell rating on shares of MannKind in a research note on Sunday, November 8th. Jefferies Group reissued a buy rating and issued a $9.00 target price on shares of MannKind in a research note on Saturday, November 14th. Zacks Investment Research raised MannKind from a hold rating to a buy rating and set a $3.50 target price on the stock in a research note on Tuesday, September 29th. Griffin Securities cut MannKind from a buy rating to a neutral rating in a research note on Tuesday, December 8th. Finally, JPMorgan Chase & Co. reaffirmed an underweight rating on shares of MannKind in a report on Thursday, January 7th. Four research analysts have rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $3.04.

Shares of MannKind (NASDAQ:MNKD) traded down 9.6279% during midday trading on Wednesday, reaching $0.7528. The company had a trading volume of 5,602,686 shares. The stock’s market capitalization is $308.09 million. The company’s 50-day moving average is $1.25 and its 200-day moving average is $3.05. MannKind has a 1-year low of $0.64 and a 1-year high of $7.88.

MannKind (NASDAQ:MNKD) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.01. During the same period in the previous year, the firm earned ($0.09) earnings per share. On average, equities research analysts forecast that MannKind will post ($0.27) EPS for the current year.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company’s product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

12 Month Chart for NASDAQ:MNKD

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for MannKind Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Co. and related companies with MarketBeat.com's FREE daily email newsletter.